Shire buys ViroPharma in $4.2 billion deal (Update)

The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.

The Dublin-based drugmaker said Monday it will pay $50 for each share of ViroPharma, which is based in Exton, Pa. That represents a 27 percent premium on the U.S. company's closing price Friday, the last trading day before the deal was announced.

Shares of ViroPharma soared before markets opened and after the deal was announced, while Shire's U.S.-traded stock also climbed.

ViroPharma focuses on serious diseases with few, if any, available therapies. Its products include Cinryze, which is used to prevent and treat attacks of hereditary angioedema, a rare genetic disorder that can cause dangerous swelling of the throat or larynx.

It also makes the seizure drug Buccolam and antibiotic Vancocin.

The company generated $428 million in worldwide revenue last year.

ViroPharma said last month that U.S. sales of Cinryze, which accounts for most of its revenue, climbed 22 percent in the third quarter to $102.2 million. It expects North American sales for the treatment to total $405 million this year.

Shire said Cinryze will act as a complement to one if its drugs, Firazyr, which treats acute hereditary angioedema attacks.

ViroPharma also is developing maribavir, a potential treatment for a virus that can lead to serious disease or death in people with compromised immune systems. The experimental drug has received an orphan drug designation from both European and U.S. regulators. That could lead to market exclusivity if the drug is approved.

The companies expect the deal to close by the end of this year, next year's first quarter or soon after that.

ViroPharma shares soared nearly 26 percent, or $10.19, to $49.57 Monday in premarket trading. The stock has more than doubled after closing 2012 at $22.76.

U.S.-traded shares of Shire climbed 3.7 percent, or $4.92, to $139.32.

Related Stories

Research Lends Hope for Patients With Rare Swelling Disease

date Aug 10, 2010

(PhysOrg.com) -- The results of two recent clinical trials offer promising treatments for sufferers of the rare genetic disease hereditary angiodema, says Jonathan Bernstein, MD, an internationally recognized allergy specialist ...

FDA relents from midodrine withdrawal plan

date Sep 06, 2010

(AP) -- Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

Huge yawn locks jaw, chokes man

date Nov 19, 2007

A British man was rushed to the hospital after his monster yawn locked his jaw, blocking his ability to breathe or swallow.

Recommended for you

Teva buying Auspex for $3.2 billion

date 2 hours ago

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

date 4 hours ago

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

US aims to cut antibiotic use

date Mar 27, 2015

US President Barack Obama on Friday rolled out plans to cut inappropriate antibiotic use by half, in an effort to tackle drug resistance.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.